Form 10 Explorer
10-Q
Quarterly Report
Actuate Therapeutics, Inc.

ACTU

NASDAQ

CIK: 1652935

File #: 001-42139

Period End: Sep 30, 2024

Fiscal Year: 2024

View on EDGAR
Balance Sheet
33 line items · 2 periods
XBRL
ItemSep 30, 2024Dec 31, 2023
ASSETS
Current assets:
Cash and Cash Equivalents
13,523,4492,958,659
Other Non-Operating Current Assets
739,33236,907
Total current assets
14,262,7812,995,566
Total assets
14,262,7812,995,566
LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current liabilities:
Accounts Payable
2,330,0053,421,840
Other Non-Operating Current Liabilities
6,096,4483,221,254
Other Current Liabilities
0277,500
Other Non-Operating Current Liabilities
70,9570
UIC License Agreement
70,957
Total current liabilities
8,497,4106,920,594
Long term liabilities:
Other Non-Operating Non-Current Liabilities
0988,049
Other Non-Operating Current Liabilities
1,692130,041
UIC License Agreement
72,649130,041
Other Non-Operating Current Liabilities
404,991404,991
Total long-term liabilities
406,6831,523,081
Total liabilities
8,904,0938,443,675
Temporary Equity
094,178,404
Stockholders’ equity (deficit):
Preferred Stock
00
Total Stockholders' Equity
202
Total Stockholders' Equity
131,292,4285,468,006
Total Stockholders' Equity
(125,933,760)(105,094,521)
Total stockholders’ equity (deficit)
5,358,688(99,626,513)
Redeemable Convertible Preferred Stocks
94,178,404
Common Stock
202
Additional Paid-in Capital
131,292,4285,468,006
Retained Earnings
(125,933,760)(105,094,521)
Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit)
14,262,7812,995,566